RETA
Reata Pharmaceuticals, Inc. Class A Common StockRETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
About: Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.
Employees: 323
Financial journalist opinion
Neutral
Accesswire
1 year ago
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / April 18, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Neutral
Accesswire
1 year ago
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / April 16, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Neutral
Accesswire
1 year ago
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / April 11, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Neutral
Accesswire
1 year ago
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / April 9, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Neutral
Accesswire
1 year ago
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / April 4, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ: RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Neutral
Accesswire
1 year ago
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / April 2, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ: RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Neutral
Accesswire
1 year ago
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / March 28, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Neutral
Accesswire
1 year ago
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / March 26, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ: RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Neutral
Accesswire
1 year ago
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ: RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Neutral
Accesswire
1 year ago
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / March 19, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Charts implemented using Lightweight Charts™